======= MAT2B =======
== Gene Information ==
* **Official Symbol**: MAT2B
* **Official Name**: methionine adenosyltransferase 2B
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=27430|27430]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q9NZL9|Q9NZL9]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=MAT2B&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20MAT2B|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/605527|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Regulatory subunit of S-adenosylmethionine synthetase 2, an enzyme that catalyzes the formation of S-adenosylmethionine from methionine and ATP. Regulates MAT2A catalytic activity by changing its kinetic properties, increasing its affinity for L- methionine (PubMed:10644686, PubMed:23189196, PubMed:25075345). Can bind NADP (in vitro) (PubMed:23189196, PubMed:23425511). {ECO:0000269|PubMed:10644686, ECO:0000269|PubMed:23189196, ECO:0000269|PubMed:23425511, ECO:0000269|PubMed:25075345}.
|Polysacc synt 2|
|RmlD sub bind|
|Epimerase|
|methionine adenosyltransferase regulator activity|
|methionine adenosyltransferase complex|
|S-adenosylmethionine biosynthetic process|
|S-adenosylmethionine metabolic process|
|one-carbon metabolic process|
|coenzyme biosynthetic process|
|sulfur compound biosynthetic process|
|cofactor biosynthetic process|
|coenzyme metabolic process|
|methylation|
|enzyme binding|
|sulfur compound metabolic process|
|cofactor metabolic process|
|drug metabolic process|
|small molecule metabolic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp48|Mubritinib 0.2μM R01 exp48]]|-1.81|
|[[:results:exp454|Bafilomycin-A1 0.009μM R08 exp454]]|1.7|
|[[:results:exp291|LLY-284 2.6μM R06 exp291]]|1.75|
|[[:results:exp436|Dynasore 7μM R08 exp436]]|1.77|
|[[:results:exp73|LJH685 5μM R02 exp73]]|1.78|
|[[:results:exp487|Hinokiflavone 12μM R08 exp487]]|1.87|
|[[:results:exp282|Fluvastatin 2.2μM R06 exp282]]|1.9|
|[[:results:exp470|Chloroquine 32μM R08 exp470]]|2.02|
|[[:results:exp329|Hydroxyurea 100μM R07 exp329]]|2.12|
|[[:results:exp350|Deferoxamine 11μM R07 exp350]]|2.44|
|[[:results:exp135|MS023 7μM R03 exp135]]|2.54|
|[[:results:exp490|Hydroxychloroquine 30μM R08 exp490]]|2.6|
|[[:results:exp134|MS023 2μM R03 exp134]]|2.76|
|[[:results:exp321|ABT-702 5μM plus Deferoxamine 11μM R07 exp321]]|2.77|
|[[:results:exp227|Cryptotanshinone 12μM R05 exp227]]|3.47|
|[[:results:exp320|ABT-702 5μM plus CoCl2 18μM R07 exp320]]|3.63|
|[[:results:exp346|CoCl2 18μM R07 exp346]]|4.11|
^Gene^Correlation^
|[[:human genes:s:slc39a8|SLC39A8]]|0.413|
Global Fraction of Cell Lines Where Essential: 0/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 4185
* **Expression level (log2 read counts)**: 5.86
{{:chemogenomics:nalm6 dist.png?nolink |}}